PRESS RELEASE - July 5, 2011
JULY 5, 2011 -- Boval Company, LP, is pleased to announce the launch of a new line of human serum albumin (HSA) products for cell culture and diagnostic applications. Boval has developed this line of HSA products specifically for cell culture growth promotion where consistency and reliability are critical. These products are built from our knowledge of albumin in media applications and are the result of scientific understanding within our laboratory and product craftsmanship for enhanced growth promotion in a chemically-defined manner. Unlike other products that contain trace elements, these cell culture grade products are produced by extensive processing of very pure and controlled HSA and modified with a lipid content in ratios determined to encourage productive growth of sensitive cells. These new HSA products are manufactured in homogenous lots under current Good Manufacturing Practices with complete traceability of raw materials and finished product. These new products can be purchased either as a formulated highly purified fatty acid free product or with an optimum lipid balance for growth promotion. Several lots are currently available for sampling. Additional information on these new products can be found in the Technical Data Sheets. For sample request or questions about HSA products, please contact us at 800-635-1706 or boval@bovalco.com.
Click here for the Tech Data Sheet for:
IM0400 & IM0450 - Enhanced Human Serum Albumin for Cell Culture and Microbiological Media
PRESS RELEASE - June 30, 2011
Boval Company, LP, a Texas-based manufacturer of cell culture and diagnostic biological raw materials announced today that it had acquired Colorado based Chata Biosystems, Inc. Chata is a leading supplier of custom solutions and instruments to the pharmaceutical analytical laboratory industry and pilot plants, specializing in HPLC media, IC media, dissolution solutions, buffer solutions and HPLC water. Cody Yarborough, Boval President, stated, “We are in the middle of building a really dynamic company with a diversified portfolio of offerings for our customers in the life sciences, biotechnology and biofuels industries and this acquisition will only build on our goal of being a complete supplier to the rapidly growing biopharmaceutical processing markets” Chata Chairman, Ted Ziemann stated: “Founder, Ed Neas, and I are very proud of the consistent high quality reputation that Chata has developed over its thirteen year history as a supplier to the life science and biofuels industries and the strong value that Chata continues to bring to our customers. We believe that combining our capabilities with another leader in its industry will create a stronger business with larger scale and the same emphasis on providing the highest quality products to a highly regulated industry.” Terms of the transaction were not disclosed. Chata manufacturing will remain in Ft. Collins in its current production facility while the headquarters will be relocated to Cleburne, Texas. Questions regarding the acquisition and rapid transition periods are to be targeted to Boval Company in Cleburne, Texas at +1(800)635-1706 or found on Boval’s website, www. bovalco.com.
For more information on Chata Biosystems, visit the website at www.chatasolutions.com.
